Dr Luke Evans

It is a pleasure to be here in an air-conditioned room while we continue this debate. It is poignant that it is so hot today, because we know how that can impact people with respiratory illnesses; we are probably talking about this issue at a very useful time. I too thank the hon. Member for Wokingham (Clive Jones) for securing this important debate. As has been said, lung cancer remains a leading cause of cancer death in the UK, but it is also one of the cancers where early detection can make the biggest difference. I know that at first hand from my first year as a junior doctor working on a respiratory ward. It was eye-opening and harrowing, but also sometimes successful. I urge anyone who has the chance to visit a respiratory ward to see how important it is—and I believe that would make a difference to smoking rates. It is great that the hon. Member for Wokingham secured the debate, and great to see the hon. Member for Strangford (Jim Shannon) secured the debate, because it is a good debate—it is a good day. This is really a success story. The Liberal Democrat spokesperson, the hon. Member for Didcot and Wantage (Olly Glover), rightly told us John’s story; because of the screening that has been put in place, there will be plenty more Johns in the future, which is exactly what we want to hear. Often we talk about the problems, but this is a really good example of something positive that has come forward, and it all started under the previous Conservative Government. The roll-out of community diagnostic centres has fundamentally changed how we diagnose disease. There are now more than 170 centres across England, expanding capacity and bringing scans closer to where people live. Nationally, they have delivered millions upon millions of additional tests and have helped to ease pressure on acute services, with the clear aim of diagnosing conditions such as cancer faster and improving patient outcomes. Only this month I went to the first year anniversary of the opening of the CDC in Hinckley, a £24 million investment that has seen 59,000 patients through its door and is expanding. That means patients do not have to travel as far into Leicester or Nuneaton, and that they get their diagnoses more quickly and in a modern tech building. That is absolutely fantastic for my community, but I know that is replicated 170 times across the country. That matters because, when it comes to diseases like lung cancer, early diagnosis is everything. The sooner we can identify a problem, the sooner we can act, and crucially, the better the chances of survival. There is a real success story to talk about. The NHS lung cancer screening programme has its roots in work started by the Conservative Government, building on more than a decade of UK research and pilot studies. Following successful trials and local pilots, NHS England launched the targeted lung health check programme in 2019, focusing on high-risk groups in areas with the worst outcomes. That approach, using mobile scanners and proactive interventions, proved effective in detecting cancer earlier and reaching underserved communities. On the back of that success, and with a formal recommendation from the UK National Screening Committee in 2022, the Government announced a national roll-out in June 2023, committing to expand the screening across England and ultimately to reach full coverage by 2030. Since then, the programme has transitioned from pilots to a full national screening service and now forms a central part of efforts to improve cancer survival. I am pleased to see that the Government are continuing on that trajectory. Why does this matter? The NHS lung cancer screening programme is now delivering at scale and showing clear results. About 2.8 million people have been invited, with 1.5 million checks completed and close to 1 million scans carried out. Some 6,000 to 7,000 cancers have been detected, roughly three quarters of which have been identified at stage 1 or 2, the earlier stages, in comparison with fewer than 30% before the programme started. About 1.4% of the scans lead to a diagnosis, demonstrating a targeted and efficient approach, and uptake stands at about 60%. In short, the programme is not only reaching those most at risk, but consistently shifting diagnosis to an earlier, more treatable stage and saving lives at a national level. As I say, we welcome the proposed expansion of the lung cancer screening programme, but it is vital that steps be taken to improve the uptake of screening and lung health checks. The fact that uptake stands at 60% means that 40% of those invited are not coming forward, and they are often the ones at highest risk. The question is why. Can the Minister set out what specific interventions the Government will introduce to increase uptake, particularly among the most deprived and hard-to-reach groups? To that end, can he confirm how the Government plan to deliver targets set in the national cancer plan, including the allocation of resources and funding for the lung cancer screening programme, over the next few years? As my new Scottish Conservative colleague, my hon. Friend the Member for Aberdeen South (Douglas Lumsden), may rightly point out, progress on lung cancer screening is uneven. England is now rolling out a full national programme; Wales has committed to an implementation, with the first invitations expected from 2027; Scotland remains at a pilot stage, with a national roll-out likely to be years away; and Northern Ireland is still in the early planning phases, without a programme in place. Given that variation, will the Minister set out what discussions are taking place across all four nations? Most importantly, what lessons are been learned from the English experience that can be actively shared to support a faster and more consistent delivery and roll-out across the UK? More broadly, this issue speaks to the need for a coherent approach to respiratory disease. Under the last Conservative Government, there was a clear attempt to take a more joined-up approach to the country’s biggest killers through a major condition strategy, which was announced in 2023. It explicitly placed chronic respiratory diseases, alongside cancer and cardiovascular disease, as one of six national priorities, recognising both its scale—it affects millions—and its contribution to avoidable ill health. A detailed framework, setting out a shift towards prevention, early diagnosis and management of those conditions, was published later that year. However, although the direction of travel was established and widely consulted on, the strategy never reached full publication or implementation, because there was a general election. This Government have taken a different route, with modern service frameworks. They have committed to developing modern service frameworks for frailty, dementia, mental health and cardiovascular disease—just a few areas—so I ask the Minister directly: will the Government develop a modern service framework for respiratory disease? If not, how do they intend to drive the same level of improvement for a condition that affects millions and underpins outcomes in lung cancer? We are all serious about improving cancer survival. Across this House, we all have that ambition, but we must match our ambition with delivery. Just like the 10-year plan, the delivery chapter is missing. I worry that the same could be argued for respiratory conditions. I just hope that I am proved wrong.